EU MDR Device Classification Guide

The classification record should begin with the intended purpose supplied by the manufacturer: indications, target patient population, users, use environment, body site, mode of action, duration of contact, and whether the product is standalone software, an accessory, a system component, or a device in its own right.

Do not classify from marketing shorthand. Check labels, instructions for use, clinical claims, software outputs, risk-management files, and product variants for claims that change the intended medical purpose. A new diagnostic, monitoring, therapeutic, invasive, implantable, or active function can move the device into a different Annex VIII rule or class.

Annex VIII combines definitions, implementing rules, and device-type rules rather than assigning classes by product category. Work through duration, invasiveness, body site, active-device function, substances, special materials, and software before selecting the class.

Duration is measured as continuous use: transient means less than 60 minutes, short term means 60 minutes to 30 days, and long term means more than 30 days. For replaceable devices, Annex VIII can count accumulated use where the manufacturer intends immediate replacement with another of the same type.

If the product is an active Annex XVI product without a medical purpose, check binding reclassification before accepting Rule 13 class I. Implementing Regulation (EU) 2022/2347 makes skin-treatment high-intensity electromagnetic radiation equipment class IIb, except hair-removal-only equipment is class IIa; adipose-tissue reduction, removal, or destruction equipment is class IIb; and covered brain-stimulation equipment is class III.

Software classification needs two decisions before the class outcome: whether the software qualifies as medical device software under the MDR, and whether it drives or influences a hardware device or is independent. Annex VIII treats software as an active device, and software that drives or influences another device falls within the same class as that device.

Rule 11 applies to software that provides information used for diagnostic or therapeutic decisions or monitors physiological processes. The risk analysis should explain the significance of the software output, the healthcare situation or patient condition, the intended population, context of use, and likely impact of incorrect information.

Classification determines the conformity assessment route, notified body involvement, technical documentation review depth, clinical evidence expectations, certificate content, and the resources needed before market placement.

As a general rule under the MDR recitals, class I conformity assessment is carried out under the manufacturer's responsibility because of lower vulnerability, while class IIa, IIb, and III devices require an appropriate level of notified body involvement. Class I devices placed on the market in sterile condition, devices with a measuring function, and reusable surgical instruments still require notified body involvement for the limited aspects stated in Article 52(7).

A classification rationale should let a reviewer reproduce the decision without interviewing the product team. The document should show the intended purpose reviewed, the Annex VIII definitions applied, each candidate rule considered, the selected class, the conformity route consequence, and the evidence that supports or excludes higher-risk rules.

Reopen the rationale when claims, labels, instructions for use, software functionality, energy delivery, body contact, material composition, duration of use, target population, clinical use environment, or combination with another device changes. The same trigger list should be connected to design-change control and notified body communication where certificates or approved technical documentation are affected.